R Squared’s Third Harmonic Bio THRD Stock Holding History

R Squared’s Portfolio THRD Stock Details THRD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-1,840	Closed	-$18.9K	–	1396
2024 Q4	$18.9K	Buy	+1,840	New	+$22.9K	0.02%	902

Other funds holding THRD

Atlas Venture Life Science Advisors Cambridge, Massachusetts $790M AUM 223.66% 1-Year Est. Return

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

BML Capital Management Zionsville, Indiana $156M AUM 129.82% 1-Year Est. Return

Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return

TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return

Newtyn Management New York $936M AUM 27.23% 1-Year Est. Return

R Squared's THRD Position: Q1 2025 in Review

R Squared sold out of Third Harmonic Bio (THRD) in Q1 2025, closing a stake of 1,840 shares — an estimated $18.9K sold.

R Squared first reported a position in THRD in Q4 2024 and held it in 1 quarter. The position peaked at $18.9K in Q4 2024. 99 funds tracked by Wall St. Rank hold THRD as of Q1 2025.

R Squared reported no remaining Third Harmonic Bio position as of Q1 2025 after selling out during the quarter.
R Squared sold 1,840 Third Harmonic Bio shares in Q1 2025, an estimated $18.9K.
R Squared first reported a position in Third Harmonic Bio in Q4 2024 and held it in 1 quarter.
R Squared's Third Harmonic Bio position peaked at $18.9K in Q4 2024.
99 funds tracked by Wall St. Rank held Third Harmonic Bio as of Q1 2025.

Based on R Squared's 13F filing for Q1 2025, filed 9 May 2025.